Cholesterol gene therapy VERVE-102: NEJM data, LDL reduction by 62% https://ymaho.com/cholesterol-gene-therapy-verve-102-nejm-data-ldl-reduction-by-62
NEJM published phase 1b results of gene therapy VERVE-102: LDL reduction by 62% after a single injection. Analysis of efficacy, risks, and prospects for patients with hypercholesterolemia. Read more.
CRISPR in vivo reduces cholesterol by 60% in VERVE-102 study https://ymaho.com/crispr-in-vivo-reduces-cholesterol-by-60-in-verve-102-study
Single infusion of VERVE-201 sustainably lowers LDL by more than 60%. Learn how CRISPR editing is changing the hypercholesterolemia therapy market. Read the analysis.
VERVE-102 gene editing reduces cholesterol by 62% — analysis https://ymaho.com/verve-102-gene-editing-reduces-cholesterol-by-62-analysis
Phase 1 results of VERVE-102: sustained LDL-C reduction up to 62% in patients with hypercholesterolemia. Analysis of market implications and forecasts. Read more.
CRISPR therapy VERVE-102 reduces cholesterol by 62% after injection https://ymaho.com/crispr-therapy-verve-102-reduces-cholesterol-by-62-after-injection
Journal NEJM published data on the drug VERVE-102: a single CRISPR injection (base editing) reduces LDL by 62% for 18 months without serious side effects. Learn details about the revolutionary therapy.
AAV gene therapy for HoFH: cholesterol reduction by 97.5% in clinical trial https://ymaho.com/aav-gene-therapy-for-hofh-cholesterol-reduction-by-97-5-in-clinical-trial
New AAV8 gene therapy NGGT006 for homozygous familial hypercholesterolemia reduced LDL-C by 97.5% in 3 weeks. Effect persists for 52 weeks. Find out who is eligible for treatment.